Duyuru • Jun 05
Abpro Holdings, Inc. Receives Delisting of Shares of Common Stock from Nasdaq Stock Market LLC On May 28, 2026, Abpro Holdings, Inc. (the “Company”) received written notification from the Nasdaq Listing and Hearing Review Council (the “Council”) that the Council had reviewed the decision of the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) and had determined to reaffirm the Panel’s decision that due to the Company not having met the terms of the Panel’s November 10, 2025 decision that the Company demonstrate compliance with the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026, the Company’s securities will be delisted from Nasdaq. The Company expects that Nasdaq may file a Form 25 with the SEC to delist the securities from Nasdaq and deregister the securities under Section 12(b) of the Securities Exchange Act of 1934, as amended in the coming days. Following suspension of trading on Nasdaq, the Company expects its common stock will continue to be eligible for quotation on the OTC Pink Market under its existing symbol, “ABP” and its public warrants under the existing symbol “ABPWW.” The Company can provide no assurances that any broker-dealer will make a market in its common stock or public warrants or that trading levels, liquidity, or quotation prices will be maintained. The Company also cautions its stockholders and public warrant holders that trading on the OTC Pink Market may be subject to limited availability of information, reduced transparency and liquidity and greater volatility. Duyuru • May 16
Abpro Holdings, Inc. announced delayed 10-Q filing On 05/15/2026, Abpro Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Apr 01
Abpro Holdings, Inc. announced delayed annual 10-K filing On 03/31/2026, Abpro Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Feb 21
Abpro Holdings, Inc. Receives Notice of Nasdaq Delisting and Trading Suspension on February 23, 2026 On February 18, 2026, Abpro Holdings, Inc. (the Company") received written notification from the Nasdaq Hearings Panel (the Panel") of the Nasdaq Stock Market LLC (Nasdaq") stating that, due to the Company not having met the terms of the Panel's November 10, 2025 decision that the Company demonstrate compliance with the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026, the Company's securities will be delisted from Nasdaq, and trading will be suspended at the open of trading on February 23, 2026. The Company has 15 days after the date it received notice of the Panel's decision to request that the Nasdaq Listing and Hearing Review Council (the Council") review the decision. The Company expects to appeal the Panel's decision. If no appeal is taken, the Company expects Nasdaq will file a Form 25 with the SEC to delist the securities from Nasdaq and deregister the securities under Section 12(b) of the Securities Exchange Act of 1934, as amended. Following suspension of trading on Nasdaq, the Company expects its common stock will be eligible for quotation on the OTC Pink Market under its existing symbol, ABP" and its public warrants under the existing symbol ABPWW." The Company can provide no assurances that any broker-dealer will make a market in its common stock or public warrants or that trading levels, liquidity, or quotation prices will be maintained. The Company also cautions its stockholders and public warrant holders that trading on the OTC Pink Market may be subject to limited availability of information, reduced transparency and liquidity and greater volatility. Duyuru • Feb 12
Abpro Holdings, Inc. Receives Non-Compliance Notice from Nasdaq As previously disclosed, on January 28, 2026, Anthony D. Eisenberg notified the Board of Directors (the Board") of Abpro Holdings, Inc. (the Company") of his resignation from the Board and all committees thereof. On January 30, 2026, Sooyoung Lee notified the Board of his resignation from the Board and all committees thereof. Following these resignations, the Board has initiated a process to identify and appoint qualified independent directors to fill the resulting vacancies and to satisfy the applicable requirements of The Nasdaq Stock Market (Nasdaq"). On February 5, 2026, the Company received written notice from Nasdaq stating that, as a result of the resignations described above, the Company is no longer in compliance with Nasdaq Listing Rule 5605(b)(1), which requires a majority of the Board to be comprised of independent directors as defined in Nasdaq Listing Rule 5605(a)(2), and Nasdaq Listing Rule 5605(c)(2), which requires the audit committee of the Board (the Audit Committee") to consist of at least three members, each of whom is an independent director under the Nasdaq Listing Rules and meets the heightened independence standards applicable to audit committee members. Furthermore, the Company is not eligible for the cure period provided under Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) because there is more than one vacancy on the Board and the Audit Committee. Accordingly, the Company's noncompliance with Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) constitutes additional bases for delisting the Company's securities from Nasdaq. The notice further stated that the Nasdaq Hearings Panel (the Panel") will consider these additional deficiencies in connection with its determination regarding the Company's continued listing on The Nasdaq Capital Market and required the Company to submit its views with respect to these matters to the Panel in writing no later than February 12, 2026. On February 5, 2026, the Company received a separate notice from Nasdaq notifying the Company that as a result of the resignations of Mr. Eisenberg and Mr. Lee, the Company no longer complies with Nasdaq's compensation committee requirements as set in Nasdaq Listing Rule 5605(d)(2)(A), which requires the Company's compensation committee (the Compensation Committee") to consists of at least two members, each of whom is an independent director under the Nasdaq Listing Rules. The notice provides that consistent with Nasdaq Listing Rule 5605(d)(4), the Company has a cure period to regain compliance, which extends until (1) the earlier of the Company's next annual shareholders' meeting or January 30, 2027; or (2) if the next annual shareholders' meeting is held before July 29, 2026, then the Company must evidence compliance no later than July 29, 2026. The Company intends to appoint qualified replacements to fill the vacancies on its Compensation Committee who satisfy the applicable requirements of the Nasdaq Listing Rules prior to the expiration of the applicable cure period. Neither of the Nasdaq notices has an immediate effect on the listing of the Company's common stock or warrants on Nasdaq. However, there can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to regain compliance with the applicable Nasdaq Listing Rules within the required time periods. Duyuru • Jan 24
Abpro Holdings, Inc. Announces Board and Committee Changes Abpro Holdings, Inc. announced that on January 16, 2026, Ian McDonald, a member of the Board of Directors (the “Board”) of the Company, notified the Board that he was resigning from the Board, including all committees of the Board. Mr. McDonald did not resign due to any disagreement with the Company, its board of directors or its management regarding any matters relating to the Company’s operations, policies or practices. On January 16, 2026, the Board appointed Dr. Byung-Hak Yoon to fill the vacancy resulting from Mr. McDonald’s resignation. Dr. Yoon will serve as a Class I director with a term ending at the 2028 annual meeting and will fill the vacancies on the Company’s Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee resulting from Mr. McDonald’s resignation. Dr. Yoon, age 51, currently serves as CEO of OQPBIOM, a biotechnology company (since March 2025), and CEO of Doowon Science Pharma (since October 2023). From June 2020 to March 2025, he served as President of CanariaBio Group. From 2022 to 2025, he served as CEO of Sejong Medica, a medical device company. From January 2020 to January 2023, he served as Chairman and CEO of Thelma Therapeutics, and from September 2018 to January 2020, he served as CEO of AXCESO Biopharma. Since January 2018, he has served as a member of the Government Project Review Committee, Ministry of SMEs and Startups, Korea, and as a member of the Government Project Review Committee, Korea Health Industry Development Institute, Korea, since February 2013. Dr. Yoon was appointed to the Board because of his extensive experience in the pharmaceutical industry. Duyuru • Jan 07
Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 Abpro Holdings, Inc. announced, together with its co-development partner Celltrion, Inc., that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABP-102 /CT-P72, Abpro's lead multispecific antibody oncology program. The IND clearance enables the initiation of a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABP-102 /CT-P72 in patients with HER2-positive solid tumors. The Phase 1 clinical study will be led by Celltrion as part of the ongoing joint strategic collaboration to ensure the robust progression of the ABP-102 /CT -P72 program. ABP-102 /CT the company is a multispecific HER2 x CD3 T-cell engager engineered to selectively target HER2-overexpressing tumor cells while engaging cytotoxic T cells, with optimized binding designed to enhance tumor selectivity and limit activity in normal HER2-low tissues. This design is intended to direct immune activity toward cancer cells while seeking to minimize damage to healthy tissue, addressing a key safety challenge that has limited the use of T-cell engagers in solid tumors. In preclinical studies, ABP-102 /CT/CT-P72 demonstrated robust antitumor activity in HER2-high tumor models, including dual xenograft models containing both HER2-high and HER2-low tumors, with selective efficacy for HER2-high tumors. The optimized CD3 binding of ABP-102/CT-P72, functionally linked with HER2-high selectivity, is intended to mitigate excessive immune activation and reduce the risk of cytokine release syndrome. Non-human primate toxicology studies showed the candidate was well tolerated at doses up to 80 mg/kg, with no significant adverse effects observed, supporting a differentiated therapeutic index. Additional preclinical evaluations demonstrated activity in tumor models representing resistance to existing HER2-directed therapies, highlighting the potential to address areas of unmet medical need. Preclinical data sets for ABP-102 /TC-P72 have been presented at major scientific meetings, including the 2025 Annual Meeting of the American Association for Cancer Research and the 2025 Annual Meeting of the Society for Immunotherapy of Cancer. Following IND clearance, Abpro and Celltrion plan to initiate a global Phase 1 clinical trial in the first half of 2026, subject to final site activation and regulatory processes. The study is expected to include dose-escalation and dose-expansion cohorts and will inform future clinical development strategies. Duyuru • Dec 16
Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers Abpro Holdings, Inc. together with its co-development partner Celltrion, Inc. announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for ABP-102/CT-P72, a HER2 x CD3 T cell engager engineered with optimized CD3 and HER2 binding to improve tumor selectivity. Pending regulatory clearance, this IND will support the initiation of a phase 1 clinical trial, anticipated to begin in 1H 2026 in patients with HER2-positive cancers including breast and gastric cancers. This submission represents a significant milestone in the companies' collaborative development of ABP- 102/CT-P72 and marks an important advance for Abpro's broader immuno-oncology pipeline. Upon FDA authorization to proceed, the planned phase 1 study will evaluate the safety, pharmacokinetics, and preliminary efficacy of ABP-102/CT-P72 in a dose-escalation and dose-expansion format. Data generated from the trial will inform dose selection and guide subsequent clinical development. Duyuru • Oct 18
Nasdaq Schedules Hearing for Abpro Holdings, Inc. Regarding Delisting Notice As previously disclosed, Abpro Holdings, Inc. (the Company") requested a hearing (the Hearing") before an independent Hearings Panel (the Panel") regarding a delisting notice in connection with its failure to comply with Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Price Requirement"). The Hearing has been scheduled for October 30, 2025. As previously disclosed, on April 10, 2025, the Company received two letters from the listing qualifications department staff of The Nasdaq Stock Market (Nasdaq"). One letter (the MVPHS Notice") indicated that based upon Nasdaq's review of the Company's Market Value of Publicly Held Shares (MVPHS") for the last 30 consecutive business days prior to the date of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities to maintain a minimum MVPHS of $15,000,000 (theMVPHS Requirement"). The second letter notified the Company that from February 20, 2025, to April 9, 2025, the Company's Market Value of Listed Securities (MVLS") was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the MVLS Requirement"). Each letter stated that the Company had 180 calendar days, or until October 7, 2025, to regain compliance. On October 14, 2025, the Company received a letter (the Notice") from Nasdaq notifying the Company that it had not regained compliance with either the MVPHS Requirement or the MVLS Requirement during the compliance period. During the Hearing, the Company will present its plans to regain compliance with the Minimum Bid Price Requirement, the MVPHS requirement and the MVLS requirement. Any further delisting action has been stayed pending the Panel's decision and/or any further extension provided by the Panel; therefore, the Notice has no immediate effect on the listing of the Company's common stock or warrants on Nasdaq. There can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to evidence compliance prior to the expiration of any extension that may be granted by the Panel. Duyuru • Oct 04
Abpro Holdings Receives Notice of Nasdaq Delisting Due to Non-Compliance with Bid Price Rule As previously reported, on April 2, 2025, Abpro Holdings, Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it no longer complied with the minimum bid price requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share. The letter stated that the Company had 180 calendar days, or until September 29, 2025, to regain compliance. On September 30, 2025, the Company received a letter from Nasdaq notifying the Company that it had not regained compliance with the Minimum Bid Price Requirement during the compliance period. Accordingly, unless the Company requests an appeal by October 7, 2025, the Company’s common stock will be scheduled for delisting at the opening of business on October 9, 2025. Accordingly, the Company intends to timely request a hearing before the appeal panel. The hearing request will stay the suspension of the Company’s securities with Nasdaq pending the Panel’s decision or any extension of time provided by the Panel to regain compliance. During the hearing, the Company will present its plans to regain compliance with the bid price and all other continued listing requirements. There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to evidence compliance prior to the expiration of any extension that may be granted by the Panel. Duyuru • May 01
Abpro Holdings, Inc., Annual General Meeting, May 20, 2025 Abpro Holdings, Inc., Annual General Meeting, May 20, 2025. Duyuru • Apr 28
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager Abpro Holdings, Inc. and Celltrion unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the American Association for Cancer Research® (AACR) Annual Meeting 2025, in the New Drugs on the Horizon session. ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-cell engager co-developed with Celltrion, is engineered to selectively target HER2-overexpressing tumors while reducing the risk of on-target, off-tumor toxicity in normal tissues. Preclinical findings presented at AACR suggest the potential of ABP-102/CT-P72 to surpass existing HER2-targeted therapies in both efficacy and safety. Key Findings: Highly Selective Tumor Killing: ABP-102/CT-P72 achieves potent cytotoxicity in HER2-overexpressing breast and gastric cancer models while significantly reducing activity against HER2-low cells, addressing a key limitation of prior HER2-targeted T-cell engagers. Enhanced Tumor Growth Inhibition: In vivo studies showed ABP-102/CT-P72 had up to a two-fold increase in tumor suppression compared to a biosimilar of runimotamab, a benchmark HER2 x CD3 bispecific antibody. Reduced Cytokine Release: Engineered for functionally monovalent CD3 binding, ABP-102/CT-P72 minimizes cytokine-related toxicities, as demonstrated by reduced cytokine release in HER2-low cell models while maintaining potent cytotoxicity in HER2-high models. Improved Tolerability: Dose escalation studies in cynomolgus monkeys confirmed that ABP-102/CT-P72 was well tolerated, even at doses exceeding 180 times the maximum tolerated dose observed with the parental antibody, suggesting a broader therapeutic window. The combination of HER2-selective T-cell activation, reduced cytokine release in HER2-low environments, and high tolerability in non-human primates underscores how ABP-102/CT-P72’s functionally monovalent CD3 binding strategy successfully mitigates on-target off-tumor toxicity. These attributes position ABP-102/CT-P72 as a potentially safer alternative to previous HER2-targeting T-cell engagers, paving the way for a broader therapeutic window in clinical trials, which are planned to start in the first half of 2026. Duyuru • Apr 09
Abpro Holdings Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market On April 2, 2025, Abpro Holdings, Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that, based on the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to September 29, 2025. If the Company does not regain compliance by September 29, 2025, the Company may be eligible for an additional 180 calendar day compliance period. If the Company does not regain compliance within the compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company intends to monitor the closing bid price of the Company’s common stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement. Duyuru • Apr 02
Abpro Holdings, Inc. announced delayed annual 10-K filing On 04/01/2025, Abpro Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Mar 09
Abpro Holdings, Inc. and Abpro Corporation Announces Termination of Ian Chan as Chief Executive Officer On March 7, 2025, Abpro Holdings, Inc. announced that it had terminated Ian Chan as Chief Executive Officer and principal executive officer of the Company, effective as of March 3, 2025. In addition, pursuant to Mr. Chan’s employment agreement with the Company’s wholly-owned subsidiary, Abpro Corporation, Mr. Chan was notified that he was terminated as Chief Executive Officer and director of Abpro Corporation, effective March 3, 2025. Duyuru • Dec 14
Abpro Holdings, Inc. announced that it expects to receive $50 million in funding from Yorkville Advisors LLC Abpro Holdings, Inc. entered into a Standby Equity Purchase Agreement with Yorkville to issue up to $50 million on December 12, 2024. Duyuru • Nov 29
Abpro Holdings, Inc. Announces Resignation of Shahraab Ahmad as Chief Financial Officer On November 21, 2024, Shahraab Ahmad notified Abpro Holdings, Inc., a Delaware corporation (the “Company”) of his resignation as the Company’s Chief Financial Officer, effective November 22, 2024.